Last reviewed · How we verify

Metronidazole Tablet

Appili Therapeutics Inc. · FDA-approved active Small molecule Under review Quality 0/100

Metronidazole Tablet is a Nitroimidazole antibiotic Small molecule drug developed by Appili Therapeutics Inc.. It is currently FDA-approved for Anaerobic bacterial infections (intra-abdominal, gynecological, respiratory), Parasitic infections (giardiasis, trichomoniasis, amebiasis), Bacterial vaginosis. Also known as: Flagyl, Metrogel, Revomet gel, No other Names.

Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after being reduced in anaerobic environments.

Metronidazole Tablet is a small molecule that inhibits DNA, classified as an inhibitor. It is used to treat various conditions, including Colorectal Cancer Stage II and III, Liver Abscess, Necrotic Primary Molars, and Surgical Site Infections, among others.

At a glance

Generic nameMetronidazole Tablet
Also known asFlagyl, Metrogel, Revomet gel, No other Names, Metro Gel
SponsorAppili Therapeutics Inc.
Drug classNitroimidazole antibiotic
TargetBacterial and parasitic DNA
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Metronidazole is activated by anaerobic organisms and protozoans through reduction of its nitro group, generating cytotoxic free radicals that damage DNA and inhibit nucleic acid synthesis. This mechanism makes it effective against anaerobic bacteria and certain parasites while having minimal activity against aerobic organisms. The drug has been widely used for over 50 years to treat infections caused by anaerobic bacteria and parasites such as Giardia and Trichomonas.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Metronidazole Tablet

What is Metronidazole Tablet?

Metronidazole Tablet is a Nitroimidazole antibiotic drug developed by Appili Therapeutics Inc., indicated for Anaerobic bacterial infections (intra-abdominal, gynecological, respiratory), Parasitic infections (giardiasis, trichomoniasis, amebiasis), Bacterial vaginosis.

How does Metronidazole Tablet work?

Metronidazole is a nitroimidazole antibiotic that disrupts bacterial and parasitic DNA by generating reactive oxygen species after being reduced in anaerobic environments.

What is Metronidazole Tablet used for?

Metronidazole Tablet is indicated for Anaerobic bacterial infections (intra-abdominal, gynecological, respiratory), Parasitic infections (giardiasis, trichomoniasis, amebiasis), Bacterial vaginosis, Clostridioides difficile infection, Helicobacter pylori infection (as part of combination therapy).

Who makes Metronidazole Tablet?

Metronidazole Tablet is developed and marketed by Appili Therapeutics Inc. (see full Appili Therapeutics Inc. pipeline at /company/appili-therapeutics-inc).

Is Metronidazole Tablet also known as anything else?

Metronidazole Tablet is also known as Flagyl, Metrogel, Revomet gel, No other Names, Metro Gel.

What drug class is Metronidazole Tablet in?

Metronidazole Tablet belongs to the Nitroimidazole antibiotic class. See all Nitroimidazole antibiotic drugs at /class/nitroimidazole-antibiotic.

What development phase is Metronidazole Tablet in?

Metronidazole Tablet is FDA-approved (marketed).

What are the side effects of Metronidazole Tablet?

Common side effects of Metronidazole Tablet include Metallic taste, Nausea, Headache, Diarrhea, Peripheral neuropathy (with prolonged use), Disulfiram-like reaction with alcohol.

What does Metronidazole Tablet target?

Metronidazole Tablet targets Bacterial and parasitic DNA and is a Nitroimidazole antibiotic.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing